Answers are grounded in this paper and cite their sources.
Evaluates cetuximab's effectiveness in irinotecan-refractory colorectal cancer, suggesting significant clinical benefits.
Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Cunningham et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: